Formulary Update
Posted on November 20, 2018
As of 1/1/19, Inflectra will replace Remicade as the new preferred product for Health New England. This change affects our Commercial and Medicaid members. Members currently on Remicade will be required to try Inflectra (first-line) and Renflexis (second-line) before they can continue Remicade. Prior approval through MagellanRx is required on all three of these products. Even if your patient has already tried Inflectra and Renflexis, you will need to contact Magellan for prior approval.
No Comments
Share:
